Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2018-11-19 Declaration of Voting R…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Results of Meeting 2 pages 323.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a communication dated 20 November 2018 from the company secretary to the ASX Limited, reporting the results of the Annual General Meeting (AGM) held on that day. It includes detailed voting results for resolutions passed at the AGM and also contains the Notice of Annual General Meeting with the agenda and resolutions to be considered. The content focuses on the announcement of voting results and the notice for the AGM, rather than the full annual report or financial statements. The document length is 2753 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-11-19 English
Re-Appointment of a Director 1 page 30.2KB
Board/Management Information Classification · 95% confidence The document is a letter dated 20 November 2018 addressed to the ASX Limited regarding the re-appointment of a director, Professor Stephen Locarnini. It references the Corporations Act and the requirement to confirm the appointment by resolution at the next Annual General Meeting. The letter states that the director has been re-appointed immediately following the AGM. The content focuses on board/management changes, specifically the appointment and re-appointment of a director. The document length is short (1792 characters) and it is a formal announcement rather than a detailed report or presentation. Therefore, it fits the category of Board/Management Information (MANG).
2018-11-19 English
Appendix 3B 13 pages 1.0MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcing new issues of securities and applying for quotation of additional securities. It includes detailed information about the class and number of securities issued, issue price, purpose, and compliance with ASX listing rules. The document is not a financial report, earnings release, or management discussion but a regulatory announcement related to capital raising and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance data, confirming it is not a mere announcement of a report but a substantive filing about new share issues.
2018-11-15 English
Presentation of BIT225-009 HIV-1 Phase 2 Data 2 pages 31.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 13 November 2018 from Biotron Limited addressed to the ASX. It informs about the acceptance of an abstract for presentation at an upcoming scientific meeting (HIV DART and Emerging Viruses 2018) and states that the presentation will be released to the market at the time of the meeting. The document is only 2534 characters long and does not contain any financial data, detailed report content, or regulatory filings. It is essentially an announcement about a forthcoming presentation rather than the presentation or report itself. Therefore, according to the MENU VS MEAL RULE, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2018-11-12 English
Appendix 3B 13 pages 1.0MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcing new issues of securities and applying for quotation of additional securities. It includes detailed information about the class and number of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. The document is not a financial report, earnings release, or management discussion but a regulatory announcement related to capital raising and share issuance. It is a formal notification of a new share issue and application for quotation, fitting the category of Capital/Financing Update filings.
2018-11-08 English
Change of Director's Interest Notice 3 pages 657.0KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y form, which is a Change of Director's Interest Notice filed under ASX Listing Rule 3.19A. It details the changes in securities holdings of a company director, including acquisitions and disposals of shares and options. The document is a regulatory filing notifying the market of insider transactions by a director, not a financial report, earnings release, or management discussion. It is specifically about director dealings in securities, which matches the definition of Director's Dealing (DIRS). The document length is 4683 characters, and it contains detailed information about the director's securities transactions, confirming it is not merely an announcement or certification but the actual notice of director's dealings.
2018-11-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.